newsfilter.io

Dave Ricks

Showing 1–3 of 3 transcripts.

  1. All-In Podcast31 min

    Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

    Dave Ricks, Chamath, Jason, Friedberg

    Eli Lilly CEO David Ricks has steered the company to an 860% market capitalization increase and record-breaking Mounjaro sales by leveraging a massive research workforce and aggressive manufacturing expansion to secure global dominance in GLP-1 therapies. While the firm faces capital shortages in the broader biotech sector, it is diversifying its pipeline beyond weight loss to address brain disorders and developing oral formulations to improve accessibility without compromising the high R&D reinvestment model Ricks defends. Personalized by Ricks' own successful treatment, the company balances aggressive clinical innovation with strategic supply chain controls to maintain its competitive edge against emerging international rivals.

  2. All-In Podcast1h 5m

    Dave Ricks, CEO of Eli Lilly | The All-In Interview

    Dave Ricks, Friedberg

    Under CEO Dave Ricks, Eli Lilly has expanded its market capitalization to $878 billion while dominating the GLP-1 weight loss market through innovations like tirzepatide and the upcoming oral drug orforglipron. These scientific breakthroughs address a global obesity crisis affecting billions, with the company investing heavily in domestic manufacturing and AI-driven research to sustain high-growth revenue projections. Despite facing political scrutiny over pricing and reimbursement limitations, Lilly is leveraging a rapid development culture and direct-to-consumer platforms to maintain industry leadership and expand treatment access.

  3. Goldman Sachs31 min

    Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

    Dave Ricks, John Waldron

    Eli Lilly CEO Dave Ricks outlines a strategic pivot from the current GLP-1 obesity drug boom to a 2030s focus on brain health and gene therapy, backed by a plan to double R&D spending to $11 billion annually. The company is accelerating development cycles by 50% through a global "follow the sun" manufacturing model and investing heavily in AI-driven discovery to overcome traditional productivity curves, while simultaneously scaling production capacity tenfold to meet demand. To secure future growth, Lilly is shifting toward talent-focused acquisitions and diversifying intellectual property protections against regulatory and political headwinds as it targets the treatment of neurodegenerative diseases and chronic conditions.